How does the covid 19 vaccine impact cosentyx's efficacy?

Does the covid-19 vaccine reduce Cosentyx effectiveness?

Cosentyx (secukinumab) blocks IL-17A, a cytokine involved in immune defense. Most inactivated or mRNA covid-19 vaccines still generate measurable antibody and T-cell responses in patients on IL-17 inhibitors, although peak titers are often lower than in healthy controls.

What happens to vaccine-induced antibody levels when patients continue Cosentyx?

Real-world studies show seroconversion rates above 80 % after two doses of mRNA vaccine in Cosentyx users. Neutralizing-antibody concentrations are reduced by roughly 20–40 % compared with untreated individuals, yet remain above the threshold linked to protection against severe disease.

Can a booster dose restore protection in Cosentyx-treated patients?

Additional mRNA doses increase antibody levels in most Cosentyx users, bringing titers closer to those seen in non-immunosuppressed controls. Current guidance recommends a third primary dose followed by age-appropriate boosters.

Why are companies challenging Cosentyx patents now?

Generic and biosimilar developers filed Paragraph IV challenges once the composition-of-matter patent (US 7,807,155) neared expiry. Litigation centers on formulation and dosing-regimen patents that extend protection into the late 2020s; outcomes will determine when interchangeable secukinumab products can launch.

When does Cosentyx exclusivity expire?

The key US patent covering secukinumab expires in 2028, with pediatric exclusivity potentially adding six months. European supplementary protection certificates run until 2027 in most member states. Biosimilar entry before these dates remains unlikely without successful patent challenges.

DrugPatentWatch.com tracks these dates and ongoing litigation.